PureTech Health Plc Debt / Equity
Cos'è Debt / Equity di PureTech Health Plc?
Debt / Equity di PureTech Health Plc è 0.51
Qual è la definizione di Debt / Equity?
Il rapporto debito è un rapporto finanziario che indica la proporzione relativa del patrimonio netto e del debito utilizzato per finanziare le attività di una società.
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
Debt / Equity di aziende nel Health Care settore su LSE rispetto a PureTech Health Plc
Cosa fa PureTech Health Plc?
PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and dementia-related psychosis; a hydrogel platform technology to treat obesity and other chronic metabolic diseases; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; a immunomodulation platform to treat chronic and acute inflammatory disorders; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a digital treatments to treat cognitive dysfunction associated with neurology and psychiatry conditions. It also provides hematopoietic stem cell based therapies to treat hematological malignancies; a voice-based technology platform to measure health when a person speaks; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; Glyph, a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Roche Holding AG; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Aziende con debt / equity simili a PureTech Health Plc
- Cenkos Securities plc ha Debt / Equity di 0.51
- Nicolas Miguet et Associes SA ha Debt / Equity di 0.51
- Allbanc Split II ha Debt / Equity di 0.51
- iHuman ha Debt / Equity di 0.51
- Element ASA ha Debt / Equity di 0.51
- Brainsway ha Debt / Equity di 0.51
- PureTech Health Plc ha Debt / Equity di 0.51
- Prataap Snacks ha Debt / Equity di 0.51
- RemSense Technologies Ltd ha Debt / Equity di 0.51
- Europa Oil & Gas () Plc ha Debt / Equity di 0.51
- Tikehau Capital ha Debt / Equity di 0.51
- Conzzeta AG ha Debt / Equity di 0.51
- Interparfums ha Debt / Equity di 0.51